Professor Hugh Barrett

Associate Dean, Research - Faculty of Medicine and Health

Hugh Barrett

Phone: +61 02 6773 4235

Mobile: 0403599067



Hugh has been a biomedical research fellow for much of his career, supported via the NIH, National Heart Foundation, NHMRC and industry. His research has focussed on lipid and lipoprotein metabolism combined with mathematical modelling, using compartment models. His research career began at the BakerIDI, moved to the University of Washington and more recently the University of Western Australia, where he was also the Associate Dean, Research in the Faculty of Health and Medical Sciences.

His research has contributed to understanding lipid and lipoprotein metabolism in a variety of human dyslipidemic states and under various interventions designed to reduce cardiovascular disease burden. Using tracer methodologies his research has described the mechanism of action of statins, fibrates, CETP inhibitors, new PPAR agonists and other lipid lowering agents on lipoprotein kinetics, primarily in subjects with the metabolic syndrome. In addition, his research and modelling of tracer data in human, animal and in vitro systems has provided insight into the pathways that are responsible for the regulation of lipid metabolism.

His present role is focussed on building research capacity, quality, output and outcomes in the Faculty of Medicine and Health at UNE.


BAgSc (LaTrobe)

PhD (Adelaide)

FAHA (Fellow of the American Heart Association)

Research Interests

Lipid and lipoprotein metabolism

Mathematical modelling

Modelling metabolic systems

Modelling biological systems that change with time

AMGEN – PCSK9 inhibitors to lower cardiovascular disease (CVD) risk

NHMRC – Interventions to lower Lp(a) concentrations and CVD risk


For a complete list of publications click here.


Editorial Boards:

Journal of Lipid Research

Journal of Clinical Endocrinology and Metabolism


Consultancy Interests

Design and analysis of lipoprotein metabolic studies to identify and quantitate metabolic pathways in basal states and following intervention. Past research projects with Pfizer, Sanofi Aventis, Merck and ongoing projects with Amgen and Regeneron.